CD8A and neoplasm: For instance, Schuler et al. reported in a study of 38 NSCLC patients treated with nivolumab alone or in combination with relatlimab that a significant increase in the proportion of GZMB+CD8+ T cells was observed only in major pathological response (MPR) patients (tumor cells ≤ 50%) after four weeks of treatment (p = 0.0002), and the effect was comparable in both monotherapy (p = 0.04) and combination therapy (p = 0.068) [101].